Response to Peginterferon-alfa 2b and Ribavirin in Japanese Patients with Chronic Hepatitis C Genotype 2
- 22 May 2011
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 56 (11), 3335-3342
- https://doi.org/10.1007/s10620-011-1750-7
Abstract
The current standard treatment for patients infected with hepatitis C virus (HCV) of genotype 2 is the combination of peginterferon (PEG-IFN) plus ribavirin (RBV) for 24 weeks.Keywords
This publication has 27 references indexed in Scilit:
- Optimal therapy in hepatitis C virus genotypes 2 and 3 patientsLiver International, 2011
- Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patientsHepatology, 2010
- New antiviral therapies for chronic hepatitis CHepatology International, 2010
- Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?Clinical Infectious Diseases, 2010
- Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis CNature Genetics, 2009
- Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection #Hepatology, 2009
- Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendationsScandinavian Journal of Infectious Diseases, 2009
- High Sustained Virologic Response Rate after Interferon Monotherapy in Japanese Hepatitis C Patients with a Low HCV RNA Titer and/or HCV Genotype 2Intervirology, 2004
- Optimal therapy of hepatitis CHepatology, 2002
- Optimal therapy of hepatitis CHepatology, 2002